Drug Trial Radar · NCT02442427
"Palivizumab Therapy for RSV-bronchiolitis"
Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Planned (sponsor's estimate)
Start
Sep 2014
Primary completion
Feb 1, 2018
Study completion Feb 1, 2018
Sponsor
- Lead sponsor
- Hamad Medical CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 3 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is a growing body of literature suggesting that monoclonal antibody could be efficacious in infants with RSV-bronchiolitis, well tolerated with no or clinically insignificant adverse effects. "The investigators hypothesize that a single dose of iv palivizumab 15 mg/kg in diagnosed infants \<3 months old with RSV bronchiolitis will result in fewer infants with readmissions to infirmary/observation or hospital for relapse during 3 weeks of follow-up after discharge".
Conditions
- Respiratory Syncytial Virus-bronchiolitis
Interventions
PalivizumabDrug
A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
PlaceboOther
An equal volume of 0.9% normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Readmission to either infirmary/observation or hospital or PICU during 3 weeks of follow-up after dischargeTime frame: 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hamad Medical Corporation
Doha, Qatar
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.